PMID- 30941882
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20210109
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 21
IP  - 8
DP  - 2019 Aug
TI  - Temporal variation of renal function in people with type 2 diabetes mellitus: A 
      retrospective UK clinical practice research datalink cohort study.
PG  - 1817-1823
LID - 10.1111/dom.13734 [doi]
AB  - AIM: To characterize the longitudinal variability of estimated glomerular 
      filtration rate (eGFR) in people with type 2 diabetes mellitus (T2DM), including 
      variation between categories and individuals. METHODS: People with T2DM and 
      sufficient recorded serum creatinine measurements were identified from the 
      Clinical Practice Research Datalink (T2DM diagnosis from 1 January 2009 to 1 
      January 2011 with 5 years follow-up); eGFR was calculated using the CKD-EPI 
      equation. RESULTS: In total, 7766 individuals were included; 32.8%, 50.2%, 12.4%, 
      4.0% and 0.6% were in glomerular filtration rate (GFR) categories G1, G2, G3a, 
      G3b and G4, respectively. Overall, eGFR decreased by 0.44 mL/min/1.73 m(2) per 
      year; eGFR increased by 0.80 mL/min/1.73 m(2) between index and year 1, then 
      decreased by 0.75 mL/min/1.73 m(2) annually up to year 5. Category G1 showed a 
      steady decline in eGFR over time; G2, G3a and G3b showed an increase between 
      index and year 1, followed by a decline. Category G4 showed a mean eGFR increase 
      of 1.85 mL/min/1.73 m(2) annually. People in categories G3-G4 moved across a 
      greater number of GFR categories than those in G1 and G2. Individual patients' 
      eGFR showed a wide range of values (change from baseline at year 5 varied from 
      -80 to +59 mL/min/1.73 m(2) ). CONCLUSION: Overall, eGFR declined over time, 
      although there was considerable variation between GFR categories and individuals. 
      This highlights the difficulty in prescribing many glucose-lowering therapies, 
      which require dose adjustment for renal function. The study also emphasizes the 
      importance of regular monitoring of renal impairment in people with T2DM.
CI  - (c) 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Spanopoulos, Dionysis
AU  - Spanopoulos D
AD  - Market Access, Boehringer Ingelheim Ltd, Bracknell, UK.
FAU - Okhai, Hajra
AU  - Okhai H
AD  - Diabetes Research Centre, University of Leicester, Leicester, UK.
FAU - Zaccardi, Francesco
AU  - Zaccardi F
AD  - Diabetes Research Centre, University of Leicester, Leicester, UK.
FAU - Tebboth, Abigail
AU  - Tebboth A
AUID- ORCID: 0000-0001-8201-3507
AD  - Market Access, Boehringer Ingelheim Ltd, Bracknell, UK.
FAU - Barrett, Brendan
AU  - Barrett B
AD  - Medical Affairs, Boehringer Ingelheim Ltd, Bracknell, UK.
FAU - Busse, Michael
AU  - Busse M
AD  - Medical Affairs, Boehringer Ingelheim Ltd, Bracknell, UK.
FAU - Webb, Joanne
AU  - Webb J
AD  - Medical Affairs, Eli Lilly and Company, Basingstoke, UK.
FAU - Khunti, Kamlesh
AU  - Khunti K
AUID- ORCID: 0000-0003-2343-7099
AD  - Diabetes Research Centre, University of Leicester, Leicester, UK.
LA  - eng
GR  - Boehringer Ingelheim Ltd/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190506
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Creatinine/blood
MH  - Databases, Factual
MH  - Diabetes Mellitus, Type 2/*blood/complications/physiopathology
MH  - Diabetic Nephropathies/*etiology
MH  - Disease Progression
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Kidney/physiopathology
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Time Factors
MH  - United Kingdom
PMC - PMC6767485
OTO - NOTNLM
OT  - UK
OT  - primary care
OT  - renal impairment
OT  - type 2 diabetes
COIS- A.T. and M.B. are employees of Boehringer Ingelheim, the study sponsor. D.S. and 
      B.B. were also employees of Boehringer Ingelheim at the time the study was 
      conducted. J.W. is an employee of Eli Lilly and Company. H.O. and F.Z. received 
      funding from the study sponsors for the analysis and conduct of the study. K.K. 
      has acted as a consultant and or speaker for Napp, Novartis, Novo Nordisk, 
      Sanofi-Aventis, Lilly and Merck Sharp & Dohme, and has received grants in support 
      of investigator and investigator-initiated trials from Novartis, Novo Nordisk, 
      Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme.
EDAT- 2019/04/04 06:00
MHDA- 2020/09/17 06:00
PMCR- 2019/09/30
CRDT- 2019/04/04 06:00
PHST- 2019/01/11 00:00 [received]
PHST- 2019/03/19 00:00 [revised]
PHST- 2019/03/31 00:00 [accepted]
PHST- 2019/04/04 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2019/04/04 06:00 [entrez]
PHST- 2019/09/30 00:00 [pmc-release]
AID - DOM13734 [pii]
AID - 10.1111/dom.13734 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2019 Aug;21(8):1817-1823. doi: 10.1111/dom.13734. Epub 2019 
      May 6.